Psychiatr. pro Praxi, 2004; 2: 93-95

Venlafaxin v liečbe depresívnych porúch v starobe

doc. MUDr. Eduard Kolibáš CSc
Klinika gerontopsychiatrie LFUK a FNsP Milosrdných bratov, Bratislava

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolibáš E. Venlafaxin v liečbe depresívnych porúch v starobe. Psychiatr. praxi. 2004;9(2):93-95.

Autor spracoval údaje o akútnej (8-týždňovej) fáze ambulantnej liečby súboru 34 pacientov s rekurentnou depresívnou poruchou (30 pacientov) a pacientov s depresívnou poruchou pri bipolárnej afektívnej poruche (4 pacienti) vo veku 65-84 rokov (priemerný vek 72,21 r.). V hodnotenom 8-týždňovom období dosiahlo remisiu 44,12 % pacientov, výrazné zlepšenie stavu sa dosiahlo u ďalších 32,35 % pacientov.

Mierne nežiaduce účinky liečby sa vyskytli u 26,47 % pacientov, stredne ťažké alebo ťažké nežiaduce účinky sa zaznamenali u 5,88 % pacientov. U žiadneho z pacientov sa nezistilo zhoršenie somatického stavu v priebehu liečby. Pozoroval sa štatisticky nevýznamný trend zvyšovania frekvencie nežiaducich účinkov liečby pri vyšších iniciálnych denných dávkach venlafaxínu a tiež štatisticky nevýznamný trend zvyšovania frekvencie remisií pri použití vyšších maximálnych denných dávok lieku. Získané údaje sa zhodujú s údajmi z kontrolovaných štúdií a potvrdzujú dobrú účinnosť, bezpečnosť a dobre tolerovanie liečby venlafaxínom pacientmi vo vyššom veku.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alexopoulos GS, Katz IR, Reynolds CF, Carpenter D, Docherty JP. Pharmacotherapy of Depressive Disorders in Older Patients. CNS Comprehensive NeuroScience, Inc, White Plains 2001: 76 s.
    2. Ames D, Tuckwell V. Psychiatric disorders among elderly patients in a general hospital. Med J Aust, 1994; 160: 671-675. Go to original source... Go to PubMed...
    3. Bramesfeld A, Adler G, Brassen S, Schnitzler M. Day-clinic treatment of late life depression. Internat J Geriatr Psychiatry, 2001; 16: 82-87. Go to original source...
    4. DeNayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol, 2002; 5: 115-120. Go to original source... Go to PubMed...
    5. Eccleston D, Scott J. Treatment, prediction of relapse and prognosis of chronic primary depression. Internat Clin Psychopharmacol, 1991; 6 (Suppl. 2): 1-10. Go to original source... Go to PubMed...
    6. Gasto C, Navarro V, Marcos T, Portella MJ, Torra M, Rodamilans M. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol, 2003; 23: 21-26. Go to original source... Go to PubMed...
    7. Grigoriadis S, Kennedy SH, Bagby RM. A comparrison of antidepressant response in younger and older women. J Clin Psychopharmacol, 2003; 23: 405-407. Go to original source... Go to PubMed...
    8. Charlier C, Pinto E, Ansseau M, Plomteux G. Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients. J Psychopharmacol, 2002; 16: 369-372. Go to original source... Go to PubMed...
    9. Katona C, Livingston G. How well do antidepressants work in older people? A systematic review of Number Needed to Treat. J Affect Disord, 2002; 69: 47-52. Go to original source... Go to PubMed...
    10. Kolibáš E. Venlafaxín - bezpečnosť a tolerovanie pacientmi pri ambulantnej liečbe. Psychiatria pre prax, 2003; 2: 87-90. Go to original source...
    11. Kořínková V, Kolibáš E, Novotný V. Venlafaxine in inpatients - sustained remission as a treatment goal. Europ Neuropsychopharmacol, 2003; 13 (suppl. 4): 243. Go to original source...
    12. Kořínková V, Kolibáš E, Novotný V. Význam vyššieho veku pre výber antidepresíva. Psychiatrie, 2003; 7 (suppl. 1): 28-29.
    13. Lowestone S, Howard R. Depression in Elderly People, M Dunitz, Ltd, London 1997: 71 s.
    14. Pidrman V. Deprese a kardiovaskulární onemocnění. Maxdorf Jessenius, Praha 2001: 42 s.
    15. Pidrman V, Látalová K, Bouček J. Milnacipran u depresivních nemocných starších 60 let. Psychiatria pre prax, 2003; 4: 260-263.
    16. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry, 2001; 178: 234-241. Go to original source... Go to PubMed...
    17. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM, 2003; 96: 369-374. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.